Establishment of therapeutic strategies to comprehensively control inflammation and bone destruction in arthritis

点击翻译按钮获取中文摘要

The pathogenesis of bone destruction associated with chronic inflammation such as rheumatoid arthritis relied on two phases; abnormal immune responses and dysregulation of bone system. I've found that the transcription regulatory factor IkappaBzeta regulates Th17 development and is expressed in several bone cells. Thus, in this study, I attempted to determine the potential of IkappaBzeta as a therapeutic target for the treatment of inflammation-associated bone destruction, using genetically modified mice. Furthermore, I tried to identify a novel target cell/ factor that regulates both inflammation and bone destruction in arthritis. This study may provide the molecular basis for a new therapeutic strategy to block not only Th17-mediated inflammation but also osteoclastic bone destruction.